News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Lung Cancer Drug Shows Survival Benefit



5/23/2011 5:06:37 PM

More than 60 percent of lung cancer patients who received Pfizer (PFE.N) Inc's crizotinib in an early stage clinical trial were still alive after two years, according to data released on Wednesday.

While the drug was not compared to other medicines or placebo -- a higher standard of clinical trial -- the results marked the first overall survival data from the closely watched Pfizer drug.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES